← All drugs
Drug · FAERS side-effect profile with label screen

Magnesium side effects: what 81,658 FDA adverse event reports show

Magnesium · Detox Toc Toc · 1,181 reaction terms · 468,178 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Detox Toc Toc

openFDA label

Who reports

81,658 reports · 62% serious · 6,009 with death outcome · 70% female

openFDA FAERS counts, all years, deduplication not applied

Used for

place enough product on hadns to cover all surfaces. rub hands together until dry. supervise children uner 6 years of age when using this product to avoid swallowing.

FDA label, Indications and Usage

What it is

Magnesium atom is an alkaline earth metal atom. It has a role as a macronutrient.

PubChem CID 5462224 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Lab value / disease marker 8No label text to screen 32
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,141 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Grip strength119272.8
210.6–353.5ROR 273.2 · calibrated p 5e-11 ✓
128.9 EB05 110.6 · IC025 +6.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=119 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Vaginal flatulence102128.6
101.3–163.2ROR 128.8 · calibrated p 2e-8 ✓
84.2 EB05 71.4 · IC025 +5.6
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=102 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Swollen joint count74110.4
84.0–145.1ROR 110.5 · calibrated p 9e-8 ✓
75.7 EB05 62.3 · IC025 +5.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=74 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Lupus vulgaris349106.6
94.0–120.7ROR 107.0 · calibrated p 7e-8 ✓
74.9 EB05 68.5 · IC025 +5.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=349 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Deep vein thrombosis postoperative550100.1
90.7–110.4ROR 100.8 · calibrated p 1e-7 ✓
71.8 EB05 66.9 · IC025 +5.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=550 · ♀ 100% (drug 70%) · 92% clinicianno trial arm names this drug
C-reactive protein25399.2
85.8–114.8ROR 99.5 · calibrated p 1e-7 ✓
71.1 EB05 64.1 · IC025 +5.8
3/3 methods agree
Lab value / disease markerserious n=253 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody13062.0
51.2–75.1ROR 62.1 · calibrated p 4e-6 ✓
49.6 EB05 42.9 · IC025 +5.1
3/3 methods agree
Lab value / disease markerserious n=130 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Swollen joint count increased60461.5
56.3–67.3ROR 62.0 · calibrated p 3e-6 ✓
49.6 EB05 46.4 · IC025 +5.4
3/3 methods agree
Lab value / disease markerserious n=604 · ♀ 100% (drug 70%) · 94% clinicianno trial arm names this drug
Rheumatic fever76654.5
50.4–58.9ROR 55.0 · calibrated p 8e-6 ✓
44.9 EB05 42.3 · IC025 +5.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=765 · ♀ 100% (drug 70%) · 94% clinicianno trial arm names this drug
Adjustment disorder with depressed mood35053.8
48.0–60.4ROR 54.1 · calibrated p 9e-6 ✓
44.4 EB05 40.7 · IC025 +5.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=346 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
X-ray abnormal30352.4
46.3–59.3ROR 52.6 · calibrated p 1e-5 ✓
43.4 EB05 39.5 · IC025 +5.2
3/3 methods agree
Lab value / disease markerserious n=303 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Facet joint syndrome47245.1
40.9–49.7ROR 45.3 · calibrated p 3e-5 ✓
38.3 EB05 35.5 · IC025 +5.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=472 · ♀ 100% (drug 70%) · 92% clinicianno trial arm names this drug
Dislocation of vertebra33244.9
40.0–50.5ROR 45.1 · calibrated p 3e-5 ✓
38.2 EB05 34.9 · IC025 +5.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=332 · ♀ 100% (drug 70%) · 90% clinicianno trial arm names this drug
Peripheral venous disease54840.7
37.2–44.6ROR 41.0 · calibrated p 5e-5 ✓
35.2 EB05 32.8 · IC025 +5.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=542 · ♀ 100% (drug 70%) · 91% clinicianno trial arm names this drug
Retinitis20135.0
30.2–40.6ROR 35.1 · calibrated p 1e-4 ✓
30.8 EB05 27.4 · IC025 +4.6
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=201 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive82633.7
31.3–36.2ROR 34.0 · calibrated p 1e-4 ✓
29.8 EB05 28.1 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious PRR 27.7 · ♀ 100% (drug 70%) · 94% clinicianno trial arm names this drug
Duodenal ulcer perforation85133.6
31.3–36.0ROR 33.9 · calibrated p 1e-4 ✓
29.7 EB05 28.1 · IC025 +4.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 27.5 · ♀ 100% (drug 70%) · 94% clinicianno trial arm names this drug
Porphyria acute16033.5
28.4–39.6ROR 33.6 · calibrated p 2e-4 ✓
29.6 EB05 26.0 · IC025 +4.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=158 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Rheumatoid factor positive64732.3
29.8–35.1ROR 32.6 · calibrated p 2e-4 ✓
28.7 EB05 26.9 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=646 · ♀ 100% (drug 70%) · 95% clinicianno trial arm names this drug
C-reactive protein abnormal62727.8
25.6–30.1ROR 28.0 · calibrated p 4e-4 ✓
25.1 EB05 23.5 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious n=627 · ♀ 100% (drug 70%) · 95% clinicianno trial arm names this drug
Muscle injury75225.8
23.9–27.8ROR 26.0 · calibrated p 6e-4 ✓
23.5 EB05 22.1 · IC025 +4.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 23.4 · ♀ 100% (drug 70%) · 93% clinicianno trial arm names this drug
Folliculitis81221.8
20.3–23.4ROR 22.0 · calibrated p 0.001 ✓
20.2 EB05 19.0 · IC025 +4.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 21.7 · ♀ 100% (drug 70%) · 92% clinicianno trial arm names this drug
Helicobacter infection80021.8
20.3–23.4ROR 22.0 · calibrated p 0.001 ✓
20.1 EB05 19.0 · IC025 +4.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.5 · ♀ 100% (drug 70%) · 92% clinicianno trial arm names this drug
Breast cancer stage iii50221.6
19.8–23.7ROR 21.8 · calibrated p 0.001 ✓
20.0 EB05 18.6 · IC025 +4.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=502 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Pemphigus95721.3
20.0–22.8ROR 21.6 · calibrated p 0.001 ✓
19.7 EB05 18.7 · IC025 +4.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 18.3 · ♀ 100% (drug 70%) · 96% clinicianno trial arm names this drug
Sleep disorder due to general medical condition, insomnia type49321.2
19.4–23.2ROR 21.3 · calibrated p 0.001 ✓
19.6 EB05 18.2 · IC025 +4.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=487 · ♀ 100% (drug 70%) · 92% clinicianno trial arm names this drug
Drug tolerance decreased19318.9
16.4–21.9ROR 19.0 · calibrated p 0.003 ✓
17.7 EB05 15.7 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=177 · ♀ 100% (drug 70%)no trial arm names this drug
Bone erosion24018.6
16.3–21.2ROR 18.6 · calibrated p 0.003 ✓
17.4 EB05 15.6 · IC025 +3.9
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=240 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Lip dry60118.4
16.9–20.0ROR 18.5 · calibrated p 0.003 ✓
17.2 EB05 16.1 · IC025 +4.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=588 · ♀ 100% (drug 70%) · 91% clinicianno trial arm names this drug
Infusion site reaction19318.2
15.7–21.0ROR 18.2 · calibrated p 0.003 ✓
17.0 EB05 15.1 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=166 · ♀ 100% (drug 70%)no trial arm names this drug
Female genital tract fistula11217.8
14.7–21.6ROR 17.8 · calibrated p 0.004 ✓
16.6 EB05 14.2 · IC025 +3.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=112 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Blood magnesium decreased54017.1
15.6–18.6ROR 17.2 · calibrated p 0.004 ✓
16.0 EB05 14.9 · IC025 +3.8
3/3 methods agree
Lab value / disease markerserious PRR 15.0no trial arm names this drug
Autoimmune disorder59717.0
15.7–18.5ROR 17.1 · calibrated p 0.004 ✓
16.0 EB05 14.9 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 15.6 · ♀ 100% (drug 70%)no trial arm names this drug
Seronegative arthritis7017.0
13.4–21.7ROR 17.0 · calibrated p 0.005 ✓
15.9 EB05 13.0 · IC025 +3.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=70 · ♀ 100% (drug 70%) · 100% clinicianno trial arm names this drug
Hand deformity79516.5
15.4–17.8ROR 16.7 · calibrated p 0.004 ✓
15.6 EB05 14.7 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 15.6 · ♀ 100% (drug 70%) · 93% clinicianno trial arm names this drug
Blepharospasm37716.5
14.9–18.4ROR 16.6 · calibrated p 0.005 ✓
15.6 EB05 14.3 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=355 · ♀ 100% (drug 70%)no trial arm names this drug
Wound infection64216.1
14.8–17.4ROR 16.2 · calibrated p 0.005 ✓
15.1 EB05 14.2 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 15.0 · ♀ 97% (drug 70%)no trial arm names this drug
Bursitis70515.9
14.7–17.1ROR 16.0 · calibrated p 0.005 ✓
15.0 EB05 14.1 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 15.9 · ♀ 97% (drug 70%)no trial arm names this drug
Live birth47915.6
14.2–17.1ROR 15.7 · calibrated p 0.006 ✓
14.7 EB05 13.7 · IC025 +3.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 16.6 · ♀ 100% (drug 70%) · 93% clinicianno trial arm names this drug
Pericarditis95115.5
14.5–16.5ROR 15.6 · calibrated p 0.006 ✓
14.6 EB05 13.9 · IC025 +3.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 13.6 · ♀ 100% (drug 70%) · 94% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Tendon disorder6424.44.1–4.7signal
Depression2,6412.42.3–2.5signal
Arrhythmia / qt1,7602.32.2–2.5signal
Fall / fracture3,4402.32.3–2.4signal
Serious infection6,8522.32.2–2.3signal
Anaemia2,6272.32.2–2.3signal
Interstitial lung disease8122.22.0–2.3signal
Liver injury2,2301.91.8–2.0raised
Thrombocytopenia1,5311.81.7–1.9raised
Hyponatraemia5591.81.6–1.9raised
Hyperglycaemia / diabetes2,3311.71.7–1.8raised
Opportunistic infection9111.71.6–1.8raised
Gi bleeding1,1921.71.6–1.8raised
Pancreatitis5211.71.5–1.8raised
Venous thromboembolism1,2401.51.4–1.6raised
Kidney injury2,5301.41.4–1.5raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Magnesium only as a background or rescue medication (NCT06042855, NCT03467425); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)8,9393.0
2.9–3.0ROR 3.2 · calibrated p 0.559
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.7 · serious PRR 3.4no trial arm names this drug
Nausea7,0172.3
2.2–2.3ROR 2.4 · calibrated p 0.850
2.3 EB05 2.2 · IC025 +1.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.2 · serious PRR 2.8no trial arm names this drug
Diarrhoea (diarrhea)6,8482.8
2.7–2.8ROR 2.9 · calibrated p 0.656
2.7 EB05 2.7 · IC025 +1.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.4 · serious PRR 3.0no trial arm names this drug
Headache6,1752.5
2.5–2.6ROR 2.7 · calibrated p 0.743
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.5 · serious PRR 3.1no trial arm names this drug
Drug ineffective (drug did not work)5,8141.1
1.1–1.2ROR 1.1 · calibrated p 0.402
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.8no trial arm names this drug
Pain5,5282.3
2.3–2.4ROR 2.4 · calibrated p 0.851
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.7 · serious PRR 2.5no trial arm names this drug
Off label use (used outside approved label)5,2391.6
1.5–1.6ROR 1.6 · calibrated p 0.700
1.5 EB05 1.5 · IC025 +0.6Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Dizziness5,1622.7
2.6–2.8ROR 2.8 · calibrated p 0.698
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.5 · serious PRR 3.0no trial arm names this drug
Dyspnoea (shortness of breath)5,0982.3
2.3–2.4ROR 2.4 · calibrated p 0.851
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.1 · serious PRR 2.4no trial arm names this drug
Arthralgia (joint pain)4,8083.0
2.9–3.1ROR 3.1 · calibrated p 0.587
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 3.0 · serious PRR 3.8no trial arm names this drug
Asthenia (weakness)4,4193.0
3.0–3.1ROR 3.2 · calibrated p 0.578
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.6 · serious PRR 3.1no trial arm names this drug
Vomiting3,8762.1
2.1–2.2ROR 2.2 · calibrated p 0.958
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.1 · serious PRR 2.4no trial arm names this drug
Malaise (feeling unwell)3,4642.0
2.0–2.1ROR 2.1 · calibrated p 0.985
2.0 EB05 2.0 · IC025 +1.0No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.0 · serious PRR 2.4no trial arm names this drug
Pain in extremity3,4073.0
2.9–3.1ROR 3.1 · calibrated p 0.604
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.8 · serious PRR 3.6no trial arm names this drug
Rash3,3212.0
1.9–2.0ROR 2.0 · calibrated p 0.952
2.0 EB05 1.9 · IC025 +0.9No label text to screen
label has no adverse-reaction text
age-adj. PRR 2.1 · serious PRR 2.8no trial arm names this drug

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Magnesium?

In FDA FAERS, the most frequently co-reported reaction terms for Magnesium are fatigue, nausea, diarrhoea, headache, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Magnesium have an FDA boxed warning?

No. The FDA label retrieved for Magnesium has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Magnesium causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.